06660.HK
AIM Vaccine Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 1.87
+1.63%Aug 24, 2026, 01:24 UTC
Aim Vaccine Co., Ltd. announced its interim results for the six months ended June 30, 2026, with revenue of RMB 351 million, down 31.9% year-on-year, and a narrowed net loss of RMB 123 million compared to a loss of RMB 131 million in the same period last year.
Source:Aug 24, 2026, 00:20 UTC
Aimi Vaccine submitted a marketing registration application to China's National Medical Products Administration for its self-developed high-titer human diploid cell rabies vaccine, based on positive Phase III clinical trial results.
Source:Aug 3, 2026, 00:17 UTC
Aimei Vaccine's wholly-owned subsidiary Aimei Honor submitted supplementary materials to the National Medical Products Administration's Center for Drug Evaluation in response to review comments on the market registration application for its serum-free iterative rabies vaccine.
Source: